4054
Poster Board III-989
Introduction
Many clinical situations are associated with the development of iron deficiency which can adversely affect energy level, physical activity, cardiovascular function, cognition, and immune responses. Oral iron, which is the primary treatment for iron deficiency, is limited by poor tolerability due to gastrointestinal (GI) side effects and resulting problems with compliance. In addition, in many patients it is not easily absorbed and does not replace iron stores rapidly enough to meet iron losses. Blood transfusions may be avoided in these patients with the use of intravenous (IV) iron. Whereas other forms of IV iron require multiple doses for complete replacement, LMWID may be administered as a total dose infusion, typically over a 4 to 6 hour period. LMWID (INFeD) is the preferred iron dextran due to the lower incidence of reported adverse reactions in the literature as compared to high (H) MWID, (DexFerrum). Numerous clinical studies of IV iron suggest that 1000 mg is an adequate dose for many patients. Our clinical practice routinely administers LMWID as a 1 g infusion over 1 hour without pre-medication. We summarize our experience with the safety and efficacy of this method of administration.
Patients and Methods
Data were collected for consecutive adult patients with iron deficiency who were treated with 1 gram of LMWID from August 2008 to May 2009. To avoid confounding variables patients who received erythropoiesis stimulating agents or chemotherapy were excluded from the analysis. Age, gender, height, weight, diagnosis, tests of iron status (serum ferritin, total iron binding capacity, serum iron, and percent transferrin saturation), hemoglobin (Hb), history of multiple drug allergies and/or iron allergies, dose of iron dextran, infusion rate, number of transfusions, and signs or reports of adverse reactions were recorded. As clinically important hypophosphatemia (serum phosphate <2mg/dL) has been reported with several IV iron preparations, we examined pre- and post-infusion phosphate levels.
Results
189 consecutive iron deficient patients (84% female, 76% white, mean age = 51 years, mean weight = 85 Kg) were included in the analysis, 15.9% of whom had multiple drug allergies (≥ 2). The most common diagnoses were: menorrhagia, chronic kidney disease, angiodysplasia, pregnancy, GI bleed, and gastric bypass; 19% of patients had multiple diagnoses. A total of 224 1-gram doses were administered over a median infusion time of 63 minutes (interquartile range 60-66 min). No pre-medication was administered except for 1 dose of methylprednisolone prior to the test dose in each of 2 patients: one with a previous reaction to HMWID, and one with drug allergies. Following administration of LMWID, there was a significant increase from baseline in Hb of 1.2 g/dL (p <0.0001, 95% confidence interval [CI]: 1.0 to 1.4) with a median follow-up time of 3 weeks. A follow-up time of ≥ 4 weeks was associated with a greater increase in Hb than < 4 weeks (1.5 vs 1.0 g/dL, p=0.013). One patient required a transfusion following severe GI bleeding secondary to angiodysplasia. Nineteen patients (10.1%) experienced 33 adverse events (AEs). The AEs were considered treatment-related in12 patients (6.3%). The most common AEs were back pain (2.6%), headache (2.1%), and nausea (1.6%). AEs were mostly transient and resolved without therapy. Five (2.6%) patients were treated for minor reactions (3 patients received 125 milligrams of methylprednisolone during or immediately following the infusion, and 2 patients received acetaminophen). There were no serious AEs, and only 1 patient discontinued treatment due to an AE (hives). The only demographic factor that was independently associated with an increased likelihood of experiencing an AE was drug allergies. Patients with a history of > 2 drug allergies were 4.3 times more likely to experience any kind of AE than other patients (95% CI: 1.1 to 16.3, p=0.031). Mean change from baseline phosphate level was 0.0 mg/dL (95% CI: -0.1 to 0.2, p=0.537) at a median follow-up time of two weeks. No patient developed hypophosphatemia.
Conclusions
Our single center experience found IV administration of 1 gram of LMWID over 1 hour is a safe and effective treatment for patients with iron deficiency with the advantages of shorter treatment period, assured compliance, and a lower incidence of side effects than oral iron. Future prospective, randomized studies will help confirm these findings.
Disclosures:
Off Label Use: The total dose infusion of low molecular weight iron dextran, although widely used, is an off label method of administration of intravenous iron. Pappadakis:Watson Laboratories: Employment. Dahl:Watson Laboratories: Employment.
